{
    "clinical_study": {
        "@rank": "99176", 
        "acronym": "HEPATHER", 
        "arm_group": {
            "arm_group_label": "hepatitis C and/or B"
        }, 
        "biospec_descr": {
            "textblock": "whole blood, serum, plasma and urine"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "-  The cohort will integrate clinical, genetic, pharmacogenomics, environmental,\n           biomarkers and behavioral data in a large number of patients and will be a leading\n           equipment for crossdisciplinary and translational research on hepatitis.\n\n        -  The cohort will be the main support for estimating the relative effects of treatments\n           and for further cost-effectiveness studies on the management and treatment options in\n           chronic HCV (Hepatitis C Virus)and HBV (Hepatitis B virus)infections."
        }, 
        "brief_title": "Therapeutic Option for Hepatitis B and C: a French Cohort", 
        "completion_date": {
            "#text": "August 2022", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Viral Hepatitis B", 
            "Viral Hepatitis C"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "General schedule of the study :\n\n        -  Prospective multicenter national study\n\n        -  Duration of inclusions: 2 years\n\n        -  Effective : 25000 patients\n\n        -  Duration of the follow-up: 8 years\n\n        -  Duration of the cohort: 10 years\n\n      Population :\n\n      Twenty-five thousands of people will be included and followed in investigator sites, 15000\n      with an hepatitis C and 10000 with an hepatitis B, according their usual follow-up of their\n      liver disease.\n\n      Design study:\n\n        -  During the recruitment visit,  demographics, clinical, biological and virological data\n           will be collected. The patient will move through several assessments involving\n           questionnaires, measurements and blood sampling.\n\n        -  Then the minimum follow-up is one medical visit per year. The follow-up (clinical data\n           and biological collections) will be driven by events or based on protocols that will be\n           developed on the cohort.\n\n        -  There is no specific treatment in this cohort.\n\n      The scientific project is structured into 4 scientific thematic axes :\n\n        -  Therapeutics:\n\n             -  To analyze the long term effects of therapy\n\n             -  To study predictors of virological response or fibrosis progression (or\n                regression)and pharmacokinetic/pharmacodynamics either in HCV or HBV treatments\n\n        -  Virology:\n\n             -  To understand the molecular mechanisms of antiviral treatment success and failure\n\n             -  To provide treatment recommendation to prevent resistance and achieve sustained or\n                definitive control of infection\n\n        -  Pathology and physiopathology :\n\n             -  To identify new pathophysiological targets responsible for chronic hepatitis\n                severity,prognosis, and evolution.\n\n             -  To validate new therapeutic combinations based on pathophysiological researches\n\n        -  Public Health:\n\n             -  To identify psychosocial and behavioral correlates of access to care, progression\n                of liver disease and of the burden of chronic viral hepatitis B and C.\n\n             -  To evaluate the cost-effectiveness of HBV and HCV treatments and quality of life"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HBV-positive patients\n\n               -  Chronic hepatitis B defined by a positive HBsAg ( surface antigen of the\n                  hepatitis B virus) for at least 6 months, with less than 30% of inactive\n                  carriers,\n\n               -  Acute hepatitis B defined as a recent appearance (<6 months) of detectable HBs\n                  Ag,\n\n               -  Patients with \"cured\" chronic hepatitis B, spontaneously or under treatment -\n                  less than 10%\n\n               -  With or without association with acute or chronic hepatitis D.\n\n          -  HCV-positive patients\n\n               -  Chronic hepatitis C defined by the positivity for anti-HCV antibodies for at\n                  least 6 months and positive HCV-RNA. At least 50% patients naive of any HCV\n                  treatment,\n\n               -  Acute hepatitis C defined by the recent appearance of HCV RNA (less than 6\n                  months) in patients with risk factors (with or without positive antibodies)\n\n               -  Patients with cured hepatitis C defined by long-term eradication, either\n                  treatment, either spontaneous, a positive anti-HCV antibodies associated to a\n                  negative RNA at two collections with 6 months interval (these patients should\n                  represent less than 10% of patients).\n\n        Exclusion Criteria:\n\n          -  HIV co-infected patients are not eligible to the cohort.\n\n          -  So-called vulnerable populations (minors, people under guardianship or protection, or\n             a private individual under protection from making legal or administrative decisions)\n\n          -  Treatment ongoing hepatitis C during or stopped since less than 3 months\n\n          -  Life expectancy of less than 1 year\n\n          -  Woman whose pregnancy is known"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "HBV-positive patients and/or HCV-positive patients"
            }
        }, 
        "enrollment": {
            "#text": "25000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01953458", 
            "org_study_id": "ANRS CO22 HEPATHER", 
            "secondary_id": "2011-A01438-33"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatitis B and C", 
            "ANRS HEPATHER French Cohort"
        ], 
        "lastchanged_date": "September 26, 2013", 
        "link": {
            "description": "Related Info", 
            "url": "http://www.anrs.fr"
        }, 
        "location": {
            "contact": {
                "email": "stanislas.pol@cch.aphp.fr", 
                "last_name": "Stanislas POL, MD, PhD"
            }, 
            "contact_backup": {
                "email": "helene.fontaine@cch.aphp.fr", 
                "last_name": "H\u00e9l\u00e8ne FONTAINE, MD"
            }, 
            "facility": {
                "address": {
                    "city": "All the Regions of the Country (36 Centers)", 
                    "country": "France"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Therapeutic Option for Hepatitis B and C: a French Cohort", 
        "overall_contact": {
            "email": "carrat@U707.jussieu.fr", 
            "last_name": "Fabrice CARRAT, MD, PhD", 
            "phone": "+33144738458"
        }, 
        "overall_contact_backup": {
            "email": "dorival@U707.jussieu.fr", 
            "last_name": "C\u00e9line DORIVAL, PhD", 
            "phone": "+33144738668"
        }, 
        "overall_official": {
            "affiliation": "H\u00f4pital Cochin, PARIS", 
            "last_name": "Stanislas POL, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France :  ANSM - Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 (French national competent authority)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "By integrating genetic, pharmacogenomics, clinical, environmental and behavioral data from a large number of patients", 
            "measure": "To improve quality and effectiveness of medical care in Hepatitis B or C taking into account new treatment options and host characteristics", 
            "safety_issue": "Yes", 
            "time_frame": "From recruitment to the end of the cohort, with a minimum of one medical visit per year (the duration of follow-up is 8 years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01953458"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To describe the epidemiology of HBV and HCV chronic infections in a context where the screening and early diagnosis of viral infection and genetic biomarkers research are increasing and evolving", 
                "safety_issue": "No", 
                "time_frame": "From recruitment to the end of the cohort, with a minimum of one medical visit per year (the duration of follow-up is 8 years)"
            }, 
            {
                "measure": "To obtain original data on efficacy and safety of new hepatitis treatments in real\u2010life with long term follow\u2010up, allowing the estimation of the public\u2010health impact of these treatments in terms of reduction of morbidity or mortality.", 
                "safety_issue": "Yes", 
                "time_frame": "From recruitment to the end of the cohort, with a minimum of one medical visit per year (the duration of follow-up is 8 years)"
            }, 
            {
                "measure": "Cross\u2010disciplinary and translational research on hepatitis based on a scientific/clinical expert network and a biobank creation", 
                "safety_issue": "No", 
                "time_frame": "From recruitment to the end of the cohort, with a minimum of one medical visit per year (the duration of follow-up is 8 years)"
            }, 
            {
                "measure": "To offer outstanding competency and resources for the design of clinical trials on specific sub\u2010populations and postmarketing (phase IV) studies", 
                "safety_issue": "Yes", 
                "time_frame": "From recruitment to the end of the cohort, with a minimum of one medical visit per year (the duration of follow-up is 8 years)"
            }, 
            {
                "measure": "To elaborate and compare cost\u2010effectiveness strategies for the management and treatment per patient class", 
                "safety_issue": "Yes", 
                "time_frame": "From recruitment to the end of the cohort, with a minimum of one medical visit per year (the duration of follow-up is 8 years)"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Bristol-Myers Squibb", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Gilead Sciences", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Janssen-Cilag Ltd.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Janssen Pharmaceuticals", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Merck Sharp & Dohme Corp.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Roche Pharma AG", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}